EGAPP Working Group Finds No Benefits From Cardiovascular Risk Scans | GenomeWeb

Consumers considering whether to purchase genetic testing services from companies that claim an ability to evaluate their "heart health" ought to put their money toward more reliable cardiovascular disease risk assessors, according to the Evaluation of Genomic Applications in Practice and Prevention Working Group. In its recently published recommendations, the working group says there is "insufficient evidence to recommend testing … genes to assess risk for cardiovascular disease" and that the "net health benefit from use of any of these tests alone or in combination is negligible."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.